



EPARTMENT OF COMMERCE UNITED STATE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR APPLICATION NO. **FILING DATE**

09/017.524

02/03/98

KUITU

018623-00509

HM22/0508 020350 TOWNSEND AND TOWNSEND AND CREW LLP TWO EMBARCADERO CENTER EIGHTH FLOOR

SAN FRANCISCO CA 94111

EXAMINER

DIBRING, M

PAPER NUMBER ART UNIT

1644

DATE MAILED:

05/09/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. **09/017,524**

Marianne DiBrino

Applica (s)

Examiner

Kubo et al

Group Art Unit 1644

Responsive to communication(s) filed on <u>Feb 16, 2000</u> This action is FINAL. ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quay/1935 C.D. 11; 453 O.G. 213. longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a). Disposition of Claim X Claim(s) 6-73 is/are pending in the applicat Of the above, claim(s) <u>6-67 and 71-73</u> is/are withdrawn from consideration Claim(s) is/are allowed. Claim(s) is/are rejected. ☐ Claim(s) ______ is/are objected to. Application Papers See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed on ______ is/are objected to by the Examiner. ☐ The proposed drawing correction, filed on is 🗌 approved 🔲 disapproved. The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). All Some* None of the CERTIFIED copies of the priority documents have been received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received: Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) ☐ Notice of References Cited, PTO-892 ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). ☐ Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-948 ☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Serial No. 09/017,524 Art Unit 1644 **DETAILED ACTION** 1. Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-305-3704. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula. Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions. 2. Applicant's election of the species VAGALVAFK (SEQ ID NO: 27), in Paper No. 11 filed 2/16/00 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claims 6-67 and 71-73 are withdrawn from further consideration by the examiner, 37 C.F.R. § 1.142(b) as being drawn to a nonelected invention. Applicant's amendment filed 2/16/00 (Paper No. 11) has necessitated the following new restriction requirement. 3. This application contains claims directed to the following patentably distinct species of the claimed Invention wherein the immunogenic peptide comprises an epitope consisting of about: A) 8 amino acid residues B) 9 amino acid residues C) 10 amino acid residues D) 11 amino acid residues These species are distinct because the epitopes are peptides with different structures, physicochemical properties and lengths. 4. This application contains claims directed to the following patentably distinct species of the claimed Invention wherein the immunogenic peptide: A) is linked to a molecule to create a compound B) is not linked to a molecule to create a compound 5. This application contains claims directed to the following patentably distinct species of the claimed Invention wherein the motif residue at position two (P2) of the epitope is: A) L

Serial No. 09/017,524 Art Unit 1644

B) M
C) I
D) V
E) A
F) S
G) T
H) G
I) N
J) C

These species are distinct because the epitopes are peptides with different structures and physicochemical properties.

6. This application contains claims directed to the following patentably distinct species of the claimed Invention wherein the motif residue at the carboxy terminus of the epitope is:

A) K

K) F L) D

B) R

C) H

These species are distinct because the epitopes are peptides with different structures and physicochemical properties.

- 7. Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.
- 8. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

While Applicant has elected the species VAGALVAFK, Applicant is required to confirm the election of the particular substituents encompassed by said peptide as they are enunciated in paragraphs 3, 5 and 6.

9. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Serial No. 09/017,524 Art Unit 1644

- 10. Should applicant traverse on the ground that the species are not patentably distinct. applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.
- 11. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marianne DiBrino whose telephone number is (703) 308-0061. The examiner can normally be reached Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Marianne DiBrino, Ph.D.

Maranne Dishinit

Patent Examiner

Group 1640

Technology Center 1600

April 27, 1999

COMMINS. SCHWADRON PRIMARY EXAMINER GROUP 1800 1 were